Dicerna Pharmaceuticals Competitors and Similar CompaniesClear all
Dicerna Pharmaceuticals's competitors and similar companies include Sangamo Therapeutics France, Morphogenesis, Abdera Therapeutics and ImmunityBio.
 Dicerna Pharmaceuticals Dicerna Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on the discovery and development of treatments for rare inherited diseases. |  Sangamo Therapeutics France Sangamo Therapeutics France (formerly known as TxCell) is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases with high unmet medical needs. |  Abdera Therapeutics Abdera Therapeutics is a biopharmaceutical company that provides an antibody engineering platform to design and develop precision radiopharmaceuticals for cancer. |  ImmunityBio ImmunityBio (formerly known as NantKwest) is a clinical-stage immunotherapy company focused on harnessing the power of the immune system using natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. | ||
Founding Date | Founding Date 2007 | Founding Date 2001 | Founding Date 1995 | Founding Date 2020 | Founding Date 2014 |
Type | Type Subsidiary | Type Subsidiary | Type Private | Type Private | Type Public |
Tags | |||||
Locations | Locations Cambridge, US HQ Boulder, US Lexington, US | Locations Valbonne, FR HQ | Locations Tampa, US HQ | Locations Menlo Park, US HQ Vancouver, CA | Locations Culver City, US HQ San Diego, US Woburn, US |
Employees | Employees 1042% decrease | Employees 7 | Employees 19 | Employees 723% increase | Employees 16116% increase |
Financial | |||||
Revenue (est.) | Revenue (est.) $164.3m (FY, 2020) | Revenue (est.) €2.2m (FY, 2017) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $113.3m (FY, 2025) |
Net income | Net income ($112.7m) (FY, 2020) | Net income (€10.9m) (FY, 2017) | Net income N/A | Net income N/A | Net income ($351.5m) (FY, 2025) |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 16m (about 8 years ago) | Latest funding round $ 110m (about 3 years ago) | Latest funding round N/A |
Total funding raised | Total funding raised $ 287.1m | Total funding raised $ 71.6m | Total funding raised $ 16m | Total funding raised $ 147.9m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Sangamo Therapeutics France
HQ
Valbonne, FR
Sangamo Therapeutics France (formerly known as TxCell) is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases with high unmet medical needs.
View company
Morphogenesis
HQ
Tampa, US
Employees
19
Morphogenesis is a clinical stage company specializing in cell and gene therapies.
View companyAbdera Therapeutics
HQ
Menlo Park, US
Employees
72↑ 3% increase
Abdera Therapeutics is a biopharmaceutical company that provides an antibody engineering platform to design and develop precision radiopharmaceuticals for cancer.
View companyImmunityBio
HQ
Culver City, US
Employees
161↑ 16% increase
ImmunityBio (formerly known as NantKwest) is a clinical-stage immunotherapy company focused on harnessing the power of the immune system using natural killer cells to treat cancer, infectious diseases, and inflammatory diseases.
View company